The Dawn of New Treatment Approaches for HER2-negative Advanced Unresectable or Metastatic Gastric or GEJ Cancers
Released On
November 9, 2023
Expires On
November 9, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology
Topic(s)
Gastric Cancer
Acknowledgement
This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.
This activity is supported by an independent medical education grant from Astellas and Merck.
Date of Release/Expiration
This activity was released on November 9, 2023 and is valid until November 9, 2024. Requests for credit must be made no later than November 9, 2024.
Credit Available
- Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
Target Audience
The primary target audience for this activity are medical oncologists, GI oncologists, gastroenterologists, oncology nurses, nurse practitioners, physician assistants, oncology pharmacists, and other clinicians involved in the management of patients with gastric or GEJ cancer.
Program Overview
Gastric and gastroesophageal junction (GEJ) cancers are difficult to treat and have poor prognosis, particularly for patients who do not carry HER2 alterations. Recent advances in targeted therapy and immunotherapy for HER2-negative advanced gastric and GEJ cancers are changing the treatment landscape for these difficult-to-treat cancers, providing new treatment options and improving patient outcomes.
Join a panel of two gastrointestinal oncologists to discuss novel biomarkers that can guide treatment of HER2-negative gastric cancer, factors that can influence therapy selection for patients, and strategies to maximize outcomes by managing treatment-associated adverse events.
Learning Objectives
After completing this activity, the participant should be better able to:
- Discuss biomarker testing and its significance in selecting therapy to manage patients with gastric and GEJ cancers
- Evaluate efficacy and safety data from practice-changing clinical trials on new and emerging targeted therapies for HER2-negative metastatic gastric and GEJ cancers
- Discuss optimum management of MSI-H/dMMR tumors with immune checkpoint inhibitors (ICIs)
- Outline adverse events associated with targeted therapies and immunotherapies for HER2-negative metastatic gastric and GEJ cancers
Faculty
Manish A. Shah, MD, FASCO
Chief, Solid Tumor Oncology Service
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Bartlett Family Professor of Gastrointestinal Oncology
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Zev Wainberg, MD
Professor of Medicine and Surgery
Co-Director, GI Oncology Program
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Accreditation Statement:
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Edcuation
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationship(s)
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Instruction for Participaton and Credit:
Estimated Time to Complete
This activity should take approximately 60 minutes to complete.
Instruction to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.
Course Viewing Requirements
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Accreditation Support
For additional information about the accreditation of this program, please visit https://partnersed.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at [email protected].
PlatformQ Health Privacy Policy
By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at [email protected]
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting [email protected] with the subject line “Data Request”
You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: www.platformqhealth.com/privacy-policy/